IRX Therapeutics - About the company
IRX Therapeutics is an acqui-hired company based in New York City (United States), founded in 1994. It operates as a Developing innovative cell therapies for advanced cancer and autoimmune diseases. IRX Therapeutics has raised $190M in funding. The company has 3275 active competitors, including 1124 funded and 776 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio.
Company Details
Developing innovative cell therapies for advanced cancer and autoimmune diseases. This therapeutics company engineers induced pluripotent stem cells (iPSCs) and differentiates them into mesenchymal stem cells (iMSCs). Their allogeneic synthetic iMSCs offer a scalable, off-the-shelf treatment solution, eliminating the need for patient-specific cell harvesting. The lead cell therapy treatment targets ovarian cancer, addressing the lack of effective targeted therapies and high recurrence rates. Another cell therapy product is designed to target inflammation and treat autoimmune diseases, offering a next-generation anti-inflammatory therapy. This approach leverages the natural tumor-homing abilities of MSCs to deliver therapeutic cytokines directly to the tumor microenvironment, triggering a strong immune response. The company is focused on transforming treatments and delivering hope through precision-guided therapeutics.
Key Metrics
Founded Year
1994
Location
New York City, United States
Stage
Acqui-Hired
Total Funding
$190M in 11 rounds
Latest Funding Round
Ranked
1755th among 3275 active competitors
Similar Companies
Sign up to download IRX Therapeutics' company profile
IRX Therapeutics's funding and investors
IRX Therapeutics has raised a total funding of $190M over 11 rounds. Its first funding round was on Mar 22, 2006.
Here is the list of recent funding rounds of IRX Therapeutics:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Aug 29, 2017 | 8520746 | Series C | 2509446 | 4510692 | 8267544 | 3885701 |
Jan 11, 2017 | 5165862 | Series C | 4786820 | 1540305 | 1249262 | 5499164 |
Nov 09, 2016 | 9131014 | Series C | 3192677 | 8732089 | 1569391 | 7975509 |
Access funding benchmarks and valuations. Sign up today!View details of IRX Therapeutics's funding rounds and investors
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
IRX Therapeutics's Competitors and alternates
Top competitors of IRX Therapeutics include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Here is the list of Top 10 competitors of IRX Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 75/100 | |
3rd | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 72/100 | |
5th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
6th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
7th | Karyopharm 2008, Newton (United States), Public | Biopharmaceutical company focused on developing and commercializing innovative cancer therapies | $98.4M | 71/100 | |
8th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 71/100 | |
9th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
10th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 | ||
1755th | IRX Therapeutics 1994, New York City (United States), Acqui-Hired | Developing innovative cell therapies for advanced cancer and autoimmune diseases | $190M | - | 30/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on IRX Therapeutics's competitors? Click here to see the top ones
IRX Therapeutics's Investments and acquisitions
IRX Therapeutics has made no investments or acquisitions yet.
Reports related to IRX Therapeutics
Here is the latest report on IRX Therapeutics's geography:
News related to IRX Therapeutics
•
Brooklyn ImmunoTherapeutics Acquires IRX TherapeuticsBioSpace•Nov 07, 2018•IRX Therapeutics, Brooklyn ImmunoTherapeutics
•
•
IRX Therapeutics Appoints Luba Greenwood to Board of DirectorsBusiness Wire•Nov 15, 2017•IRX Therapeutics
•
•
•
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about IRX Therapeutics
Explore our recently published companies
- Wisdom Square Technologies - New Hyde Park based, 2008 founded, Unfunded company
- Fruverpack - Almoradi based, 1992 founded, Unfunded company
- AERA - Bouxwiller based, 1979 founded, Unfunded company
- Divine Hindu - Ujjain based, 2023 founded, Unfunded company
- Globaldigitalpartner.com - 2013 founded, Unfunded company
- OROK - Bourgoin Jallieu based, 2018 founded, Deadpooled company
